BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 35046949)

  • 1. O-Acetyl-GD2 as a Therapeutic Target for Breast Cancer Stem Cells.
    Cheng JY; Hung JT; Lin J; Lo FY; Huang JR; Chiou SP; Wang YH; Lin RJ; Wu JC; Yu J; Yu AL
    Front Immunol; 2021; 12():791551. PubMed ID: 35046949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2
    Ly S; Anand V; El-Dana F; Nguyen K; Cai Y; Cai S; Piwnica-Worms H; Tripathy D; Sahin AA; Andreeff M; Battula VL
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant phyllodes tumors display mesenchymal stem cell features and aldehyde dehydrogenase/disialoganglioside identify their tumor stem cells.
    Lin JJ; Huang CS; Yu J; Liao GS; Lien HC; Hung JT; Lin RJ; Chou FP; Yeh KT; Yu AL
    Breast Cancer Res; 2014 Mar; 16(2):R29. PubMed ID: 24670249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors.
    Chang WW; Lin RJ; Yu J; Chang WY; Fu CH; Lai A; Yu JC; Yu AL
    Breast Cancer Res; 2013 May; 15(3):R39. PubMed ID: 23663564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells.
    Dillard C; Kiyohara M; Mah V; McDermott SP; Bazzoun D; Tsui J; Chan AM; Haddad G; Pellegrini M; Chang YL; Elshimali Y; Wu Y; Vadgama JV; Kim SR; Goodglick L; Law SM; Patel DD; Dhawan P; O'Brien NA; Gordon LK; Braun J; Lazar G; Wicha MS; Wadehra M
    Mol Cancer Ther; 2020 Aug; 19(8):1682-1695. PubMed ID: 32451329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRD4/nuclear PD-L1/RelB circuit is involved in the stemness of breast cancer cells.
    Kim SL; Choi HS; Lee DS
    Cell Commun Signal; 2023 Nov; 21(1):315. PubMed ID: 37924094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist.
    Prud'homme GJ; Glinka Y; Toulina A; Ace O; Subramaniam V; Jothy S
    PLoS One; 2010 Nov; 5(11):e13831. PubMed ID: 21072210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
    Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P
    BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells.
    Qiu M; Peng Q; Jiang I; Carroll C; Han G; Rymer I; Lippincott J; Zachwieja J; Gajiwala K; Kraynov E; Thibault S; Stone D; Gao Y; Sofia S; Gallo J; Li G; Yang J; Li K; Wei P
    Cancer Lett; 2013 Jan; 328(2):261-70. PubMed ID: 23041621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability.
    Croker AK; Goodale D; Chu J; Postenka C; Hedley BD; Hess DA; Allan AL
    J Cell Mol Med; 2009 Aug; 13(8B):2236-2252. PubMed ID: 18681906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells.
    Liang YJ; Ding Y; Levery SB; Lobaton M; Handa K; Hakomori SI
    Proc Natl Acad Sci U S A; 2013 Mar; 110(13):4968-73. PubMed ID: 23479608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis.
    Battula VL; Shi Y; Evans KW; Wang RY; Spaeth EL; Jacamo RO; Guerra R; Sahin AA; Marini FC; Hortobagyi G; Mani SA; Andreeff M
    J Clin Invest; 2012 Jun; 122(6):2066-78. PubMed ID: 22585577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.
    Keysar SB; Le PN; Miller B; Jackson BC; Eagles JR; Nieto C; Kim J; Tang B; Glogowska MJ; Morton JJ; Padilla-Just N; Gomez K; Warnock E; Reisinger J; Arcaroli JJ; Messersmith WA; Wakefield LM; Gao D; Tan AC; Serracino H; Vasiliou V; Roop DR; Wang XJ; Jimeno A
    J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27634934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of CXCR7 inhibits proliferative capacity and stem cell-like properties in breast cancer stem cells.
    Tang X; Li X; Li Z; Liu Y; Yao L; Song S; Yang H; Li C
    Tumour Biol; 2016 Oct; 37(10):13425-13433. PubMed ID: 27460092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The natural agent 4-vinylphenol targets metastasis and stemness features in breast cancer stem-like cells.
    Leung HW; Ko CH; Yue GG; Herr I; Lau CB
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):185-197. PubMed ID: 29777274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
    Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
    FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB.
    Wei L; Liu TT; Wang HH; Hong HM; Yu AL; Feng HP; Chang WW
    Breast Cancer Res; 2011 Oct; 13(5):R101. PubMed ID: 22023707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
    Koziel JE; Herbert BS
    Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
    Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
    Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphosulindac (OXT-328) selectively targets breast cancer stem cells in vitro and in human breast cancer xenografts.
    Zhu C; Cheng KW; Ouyang N; Huang L; Sun Y; Constantinides P; Rigas B
    Stem Cells; 2012 Oct; 30(10):2065-75. PubMed ID: 22653497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.